|
Synonyms: BMS-936557 | MDX-1100
Compound class:
Antibody
Comment: Eldelumab (BMS-936557 and formerly MDX-1100) is a a fully human monoclonal antibody targeting the chemokine CXCL10 (a.k.a. interferon-γ-inducible protein-10 or IP-10) [1]. It is being investigated for its anti-inflammatory action in autoimmune conditions.
BLAST peptide sequence analysis reveals exact matches with heavy and light chain variable regions claimed in patent US8258266, and identify eldelumab as clone 6A5 [1]. |
| No information available. |
Summary of Clinical Use  |
| Eldelumab has been evaluated in Phase 2 clinical trials for rheumatoid arthritis [3] and ulcerative colitis (NCT00656890) [2]. The antibody showed efficacy in both conditions. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Eldelumab potently binds CXCL10 and prevents it from binding to its receptor CXCR3. CXCR3 is expressed only on activated T cells. Antibody-induced blockade of CXCR3 activation is expected to produce an anti-inflammatory effect. |
